Nalu Medical, a Carlsbad, CA-based private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced the closing of an incremental $20M in equity in Series E funding from new investor B Capital.
The round, which brought the total amount to $85M was led by Novo Holdings with $65M of the total closing in late-December 2023. Also participating in the round were all existing investors Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners.
The company intends to use the funds to accelerate commercial growth, expand clinical and health-economic evidence, continue product development, and scale operations.
Led by President and CEO Tom West, Nalu is a medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain. The Nalu Neurostimulation System delivers gentle electrical pulses to the nervous system to modulate pain signals before they get to the brain. It was designed to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians.
FinSMEs
06/03/2024